Advertisement
Finance
Subscribe to Finance

The Lead

Astellas to Pay $7.3M Settlement

April 17, 2014 8:16 am | News | Comments

The U.S. Justice Department announced Wednesday that Astellas will pay $7.3 million to resolve allegations involving the marketing of the drug Mycamine.                  

Pharmaceutical Printing Plant in Indiana to Close

April 17, 2014 8:01 am | News | Comments

The company that owns an Evansville, Indiana printing plant says it will be shutting it down in...

Judge Blocks Massachusetts Ban on Painkiller

April 16, 2014 8:26 am | by STEVE LeBLANC, Associated Press | News | Comments

The judge issued a preliminary injunction Tuesday after Zogenix argued in a lawsuit that the ban...

BioAlliance Pharma and Topotarget Announce Merger Agreement

April 16, 2014 8:22 am | News | Comments

BioAlliance Pharma SA and Topotarget A/S today announced their intention to merge to create an...

View Sample

FREE Email Newsletter

QIAGEN Announces Facility Changes

April 16, 2014 8:13 am | News | Comments

QIAGEN today announced plans to combine its three Maryland sites into two campuses and invest an additional $10 million to accommodate expected future growth. The company will close its current site at Gaithersburg, Maryland and move the Gaithersburg activities to nearby Germantown, Maryland, by early 2015.

Epirus and Zalicus Announce Merger Agreement

April 16, 2014 8:08 am | News | Comments

Epirus Biopharmaceuticals, Inc. and Zalicus Inc., announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction.      

Manufacturing Technology Orders Down in February

April 15, 2014 8:49 am | News | Comments

February U.S. manufacturing technology orders totaled $354.40 million according to AMT - The Association For Manufacturing Technology. This total, as reported by companies participating in the USMTO program, was down 6.6% from January and down 6.2% when compared with the total of $377.82 million reported for February 2013. With a year-to-date total of $733.82 million, 2014 is down 0.6% compared with 2013.

Advertisement

Prosonix Licenses Products to Mylan

April 15, 2014 8:45 am | News | Comments

PSX1001 and PSX1050, which are the first products to emerge from Prosonix's innovative and proprietary particle engineering platform, are being developed as generic versions to GlaxoSmithKline's pressurized metered dose inhalers (pMDI) Flixotide® and Flovent®, respectively.

Report Projects Health Care Costs to Dip Slightly

April 15, 2014 8:13 am | by ANDREW TAYLOR, Associated Press | News | Comments

The Congressional Budget Office predicts that health insurance subsidies under the so-called "Obamacare" plan will total a little more than $1 trillion over the next 10 years, instead of almost $1.2 trillion initially estimated.    

DesignMedix Awarded $3M to Develop Low-Cost, Safe Malaria Drug

April 15, 2014 8:00 am | News | Comments

DesignMedix, Inc., a biotech startup with ties to Portland State University, received a grant for almost $3 million from the National Institutes of Health to continue development and manufacture of a new anti-malarial drug.     

Johnson & Johnson Reports 2014 First-Quarter Results

April 15, 2014 7:56 am | News | Comments

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%.  Domestic sales increased 2.2%.  International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

FDA Extends Market Exclusivity of KUVAN Powder for Oral Solution and Tablets

April 14, 2014 8:22 am | News | Comments

BioMarin Pharmaceutical today announced that the FDA granted KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets a six-month pediatric exclusivity extension. The FDA action extends KUVAN's market exclusivity to June 2015 and is based on studies submitted in response to a written request by the FDA to investigate the use of KUVAN in pediatric patients from birth to age 6

Advertisement

Moberg Pharma Acquires Rights to Topical Formulation for Treatment of Oral Pain

April 14, 2014 7:58 am | News | Comments

Moberg Pharma AB has entered into a definitive agreement with Oracain II Aps (Denmark) to acquire all assets and global rights to a novel and patent pending oral formulation of the proven substance bupivacaine, for the treatment of pain in the oral cavity.

Adamas Pharma Rises After IPO Raises $48M

April 11, 2014 11:22 am | by Associated Press | News | Comments

Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.                                  

Biotech Drops Again

April 11, 2014 10:58 am | by MATTHEW CRAFT, AP Business Writer | News | Comments

Biotech and Internet stocks tumbled again Thursday, and the broader market followed. After a two-day respite, investors again started dumping shares of cutting-edge drug companies and other industries that have soared over the past year.

Vetter Launches New Clinical Syringe Packages

April 10, 2014 8:35 am | News | Comments

Vetter, a contract development and manufacturing organization (CDMO), has introduced two clinical syringe packages that make it easier to start syringe development earlier in the drug development process.        

NJ Men Sentenced for Roles in Pharmaceutical Insider Trading Case

April 10, 2014 8:30 am | News | Comments

Two New Jersey men who prosecutors say were primary players in a network that illegally traded on insider tips from pharmaceutical executives have been sentenced to prison.              

Advertisement

Acura Pharmaceuticals Announces Return of Product Rights

April 10, 2014 8:22 am | News | Comments

Acura Pharmaceuticals, Inc. announced today a letter of agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's AVERSION® Technology and the return to Acura of the FDA approved Oxecta® (oxycodone HCl) product.

Investors Shed Biotech Stocks

April 9, 2014 11:34 am | by KEN SWEET, AP Markets Writer | News | Comments

Technology and biotechnology companies, high-flying stocks over the last two years, have been beaten down the last three weeks. Many are now in bear territory, which is when a stock falls more than 20 percent from a recent high.                       

Pfizer & Alcoa Are Big Market Movers

April 8, 2014 11:24 am | by Associated Press | News | Comments

Pfizer and Questcor Pharmaceuticals were just a couple of the companies that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market.                                 

Stocks Drift; Eli Lilly Falls

April 8, 2014 11:21 am | by Associated Press | News | Comments

Stocks are drifting mostly higher in early trading on Wall Street as the market stabilizes after a three-day slump.                                          

Arkansas to Ask Court to Reconsider Drug Fine

April 3, 2014 6:29 pm | by Andrew Demillo - Associated Press - Associated Press | News | Comments

Arkansas Attorney General Dustin McDaniel said Thursday he plans to ask the state Supreme Court to reconsider its decision tossing out a $1.2 billion judgment against drugmaker Johnson & Johnson over the marketing of the antipsychotic drug Risperdal.

Maine Supreme Court Upholds HoltraChem Cleanup

April 3, 2014 3:31 pm | News | Comments

A pharmaceutical company must complete the cleanup of the former HoltraChem Manufacturing Co. plant in Orrington, Maine's highest court said Thursday.                 

$1,000-a-Day Hepatitis C Drug Is a Blockbuster

April 3, 2014 8:56 am | Videos | Comments

Runaway demand for a life-saving hepatitis C treatment that costs $1,000 a day could send insurers' earnings per share down by double-digit percentages this year.               

Health Leaders on Drug Company Boards; A Conflict?

April 1, 2014 5:32 pm | by Lindsey Tanner - AP Medical Writer - Associated Press | News | Comments

Leaders of many U.S. academic medical centers sit on the boards of some of the world's biggest drug companies, which a study suggests raises the potential for worrisome conflicts of interest. Industry board members oversee company decision-making and have a financial responsibility to company shareholders, the study authors note.

Actavis Acquires Silom Medical Company

April 1, 2014 8:56 am | News | Comments

Actavis today announced that it has acquired Silom Medical Company, a privately held generic pharmaceutical company focused on developing and marketing therapies in Thailand, for approximately $100 million in cash.      

RestorGenex Completes Acquisition of Two Biopharma Companies

April 1, 2014 8:45 am | News | Comments

RestorGenex Corporation announced today the closing of its acquisition of two biopharmaceuticals companies, Paloma Pharmaceuticals, Inc. and VasculoMedics, Inc.                

Doctors Get Temporary Medicare Fix

April 1, 2014 8:14 am | by ANDREW TAYLOR, Associated Press | News | Comments

Congress once again has given doctors temporary relief from a flawed Medicare payment formula that threatened them with a 24 percent cut in their fees.                 

EMD Serono Enters into Research Agreement with Pfizer and Broad Institute

April 1, 2014 8:04 am | News | Comments

EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, today announced they have signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading